Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway

被引:95
作者
Yan, Jun
Yu, Cheng-Tai
Ozen, Mustafa
Ittmann, Nlichael
Tsai, Sophia Y.
Tsai, Ming-Jer
机构
[1] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[3] Baylor Coll Med, Program Dev, Houston, TX 77030 USA
[4] Baylor Coll Med, Baylor Prostate Canc Specialized Programs Res Exc, Houston, TX 77030 USA
关键词
D O I
10.1158/0008-5472.CAN-06-2442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Steroid receptor coactivator (SRC)-3, also called amplified in breast cancer 1, is a member of the p160 nuclear receptor coactivator family involved in transcriptional regulation of target genes. SRC-3 is frequently amplified and/or overexpressed in hormone-sensitive and hormone-insensitive tumors. We reported previously that SRC-3 stimulated prostate cell growth in a hormone-independent manner through activation of AKT signaling pathway. However, the underlying mechanism remains undefined. Here, we! exploited the mifepristone-induced SRC-3 LNCaP prostate cancer cell line generated in our laboratory to identify SRC-3-regulated genes by oligonucleotide microarray analysis. We found that SRC-3 up-regulates the expression of multiple genes in the insulin-like growth factor (IGF)/AKT signaling pathway that are involved in cell proliferation and survival. In contrast, knockdown of SRC-3 in PC3 (androgen receptor negative) prostate cancer cells and MCF-7 breast cancer cells reduces their expression. Similarly, in prostate glands of SRC-3 null mice, expressions of these components in the IGF/AKT signal pathway are also reduced. Chromatin immunoprecipitation assay revealed that SRC-3 was directly recruited to the promoters of these genes, indicating that they are direct targets of SRC-3. Interestingly, we showed that recruitment of SRC-3 to two target promoters, IRS-2 and IGF-I, requires transcription factor activator protein-1 (AP-1). Taken together, our results clearly show that SRC-3 and AP-1 can coordinately regulate the transcription of multiple components in the IGF/AKT pathway to ensure ligand-independent cell proliferation and survival of cancer cells.
引用
收藏
页码:11039 / 11046
页数:8
相关论文
共 51 条
[31]  
2-C
[32]   IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation [J].
Reiss, K ;
Wang, JY ;
Romano, G ;
Furnari, FB ;
Cavenee, WK ;
Morrione, A ;
Tu, X ;
Baserga, R .
ONCOGENE, 2000, 19 (22) :2687-2694
[33]   Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells [J].
Reiss, K ;
Wang, JY ;
Romano, G ;
Tu, X ;
Peruzzi, F ;
Baserga, R .
ONCOGENE, 2001, 20 (04) :490-500
[34]   Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis [J].
Renehan, AG ;
Zwahlen, M ;
Minder, C ;
O'Dwyer, ST ;
Shalet, SM ;
Egger, M .
LANCET, 2004, 363 (9418) :1346-1353
[35]  
Sakakura C, 2000, INT J CANCER, V89, P217
[36]   Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2 [J].
Sun, HZ ;
Tu, X ;
Prisco, M ;
Wu, A ;
Casiburi, I ;
Baserga, R .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (03) :472-486
[37]   TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1 [J].
Takeshita, A ;
Cardona, GR ;
Koibuchi, N ;
Suen, CS ;
Chin, WW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (44) :27629-27634
[38]  
Tanner MM, 2000, CLIN CANCER RES, V6, P1833
[39]   The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function [J].
Torchia, J ;
Rose, DW ;
Inostroza, J ;
Kamei, Y ;
Westin, S ;
Glass, CK ;
Rosenfeld, MG .
NATURE, 1997, 387 (6634) :677-684
[40]   High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene [J].
Torres-Arzayus, MI ;
de Mora, JF ;
Yuan, J ;
Vazquez, F ;
Branson, R ;
Rue, M ;
Sellers, WR ;
Brown, M .
CANCER CELL, 2004, 6 (03) :263-274